Baker McKenzie advises Ariceum Therapeutics on Extension of Series A Financing to EUR 47.75 million

Baker McKenzie advised Ariceum Therapeutics (Ariceum) on the successful completion of a Series A extension financing, raising a further EUR 22.75 million, following the EUR 25 million Series A financing announced in June 2022.

Ariceum, a Berlin-based private biotechnology company, intends to use the proceeds from the financing to advance its clinical pipeline and to further build the company focusing on its lead asset and proprietary peptide derivative, Satoreotide, as well as building a pipeline of further projects. New investors Andera Partners and Earlybird Venture Capital join existing investor, Pureos Bioventures in the financing extension. Olivier Litzka, Partner at Andera Partners, and Christoph Massner, Principal at Earlybird, will join the Ariceum advisory board as additional board members.

Baker McKenzie advised Ariceum Therapeutics on all legal aspects of with the financing.

“Together with our client and with our team of specialist corporate and life sciences lawyers, we were able to successfully secure further funds for Ariceum and pave the way for developing a treatment for patients suffering from certain hard-to-treat cancers,” comments Julia Braun, LL.M., lead partner on the transaction.

Baker McKenzie’s Corporate / M&A and life science teams regularly advise big pharma, financial and strategic investors and early-stage biotech companies on domestic and international healthcare transactions.
Most recently, Baker McKenzie advised life science investors Seamless Therapeutics on a USD 12.5 million financing and in-licensing from TU Dresden, Andera Partners, Evotec and Fund+ on the successful closing of a EUR 60 million (USD 63 million) Series B financing of Tubulis GmbH, Allecra Therapeutics on an exclusive license and supply agreement with ADVANZ PHARMA, MODAG on a strategic collaboration with Teva, Chord Therapeutics on its sale to Merck KGaA, LSP as lead investor on a EUR 20 million Series A Equity Financing in Innovative Molecules, Numab Therapeutics on a CHF 100 million Cross Over Financing, CatalYm on a EUR 50 million Series B financing led by Vesalius Capital, Casdin Capital on a USD 50 million extension of the Series B Equity Financing in DNA Script, and Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie.

Legal Advisor to Ariceum Therapeutics GmbH:

Baker McKenzie

Lead:

Julia Braun (Corporate/M&A, partner, Munich)

Team:

Corporate/M&A: Erik Kuhn (associate, Munich), Anna Dzik (associate, Munich)